Jean-Luc Canon

ScholarGPS® ID: 33484960584901

Affiliation
Amgen Inc., Thousand Oaks, United States
Affiliation History

Field
Medicine
Discipline
Oncology
Top Specialties
Cancer | Breast Cancer | Chemotherapy | Colorectal Cancer | Lung Cancer | Metastatic Breast Cancer | Neoplasm | Trastuzumab | Bevacizumab | Anemia | Mutation | Radiation Therapy | Capecitabine | Docetaxel | Fluorouracil
Metrics Summary
Publication Count
152
Predicted Citations
8,826
Predicted h-index
36
Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

  • Publications
  • Books
  • Patents
  • NIH/NSF
You must register and claim your profile to add or remove publications from it.
... publications
FILTER BY:
Year
Type
Specialty
Affiliations
Access
Co-Authors
Add
Delete
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization. (journal article)
Forget, Frederic | Morales Murillo, Serafin | Ibrahim, Nuhad K. | Doger de Spéville Uribe, Bernard | Marathe, Omkar | Canon, Jean-Luc Re | Chalasani, Pavani | Papadimitriou, Konstantinos | Oliveira, Mafalda | Seguí, Elia | Triebel, Frederic
Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS1125-TPS1125 (2024).
10.1200/JCO.2024.42.16_suppl.TPS1125
Cite | Source
200P Testing a higher dose (90 mg s.c.) of eftilagimod alpha, a soluble LAG-3 protein in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003 (journal article)
Murillo, S. Morales | Forget, F. | Solis, E. Segui | Ibrahim, N.K. | Doger de Spéville, B. | Canon, J-L. | Chalasani, P. | Papadimitriou, K. | Oliveira, M. | Sanchez-Rovira, P. | ... | Triebel, F.
ESMO Open, volume 9 (2024).
10.1016/j.esmoop.2024.103222
Cite | Source
178P Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy/immunotherapy (journal article)
Birchall, C. | Merhi, A. | Devaux, A. | Bar, I. | Haussy, S. | Petrone, D. | Beniuga, G. | Delree, P. | Canon, J-L. | Devos, M. | ... | Carrasco, J.
Immuno-Oncology and Technology, volume 20 (2023).
10.1016/j.iotech.2023.100637
Cite | Source
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study (journal article)
Joris, S. | Denys, H. | Collignon, J. | Rasschaert, M. | T’Kint de Roodenbeke, D. | Duhoux, F.P. | Canon, J.-L. | Tejpar, S. | Mebis, J. | Decoster, L. | ... | De Grève, J.
ESMO Open, volume 8, issue 6, pages 102041- (2023).
10.1016/j.esmoop.2023.102041
Cited by (7) | Cite | Source
201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study (journal article)
Decoster, L. | Aftimos, P.G. | Rottey, S. | Prenen, H. | Collignon, J.J. | Mebis, J. | Canon, J-L. | Fastenaekels, V. | Cappoen, N. | Joris, S.R. | De Grève, J.
Annals of Oncology, volume 34 (2023).
10.1016/j.annonc.2023.09.2924
Cite | Source
152P Efficacy of olaparib in advanced cancers with germline or somatic tumor mutations in BRCA1, BRCA2, CHEK2 and ATM: A Belgian precision tumor-agnostic phase II study (journal article)
Joris, S.R. | Denys, H. | Collignon, J.J. | Rasschaert, M. | T'Kint de Roodenbeke, D. | Duhoux, F.P. | Canon, J-L. | Tejpar, S. | Mebis, J. | Decoster, L. | ... | De Grève, J.
Annals of Oncology, volume 34 (2023).
10.1016/j.annonc.2023.09.2876
Cite | Source
131P Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer: An analysis of the Unicancer Neopal phase II study (journal article)
Frenel, J.S. | Vincent-Salomon, A. | Lemonnier, J. | D'Hondt, V. | Desmoulins, I. | Heudel, P.E. | Duhoux, F.P. | Emile, G. | Mouret Reynier, M.A. | Dalenc, F. | ... | Cottu, P.H.
ESMO Open, volume 8, issue 1, pages 101470- (2023).
10.1016/j.esmoop.2023.101470
Cite | Source
255TiP AIPAC-003: A randomized, double-blind, placebo-controlled phase III trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization (journal article)
Duhoux, F.P. | Ibrahim, N.K. | Papadamitriou, K. | Canon, J-L. | Morales, S. | Sanchez-Rovira, P. | Oliveira, M. | Doger de Spéville, B. | Houtsma, D. | Beeker, A. | ... | Triebel, F.
ESMO Open, volume 8, issue 1, pages 101443- (2023).
10.1016/j.esmoop.2023.101443
Cited by (1) | Cite | Source
219P Spatial sequencing of T cell repertoire in breast cancer (journal article)
Merhi, A. | Rosmaninho, P. | Bar, I. | Birchall, C. | Haussy, S. | Petrone, D. | De Wever, J. | Devaux, A. | Canon, J-L. | Beniuga, G. | ... | Carrasco, J.
Immuno-Oncology and Technology, volume 16 (2022).
10.1016/j.iotech.2022.100330
Cite | Source
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast (journal article)
Agostinetto, Elisa | Nader-Marta, Guilherme | Paesmans, Marianne | Ameye, Lieveke | Veys, Isabelle | Buisseret, Laurence | Neven, Patrick | Taylor, Donatienne | Fontaine, Christel | Duhoux, Francois P | ... | Aftimos, Philippe
Future Oncology, volume 18, issue 22, pages 2383-2392 (2022).
10.2217/fon-2022-0358
Cited by (8) | Cite | Source
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olapari (journal article)
Guiu Lahaye, Severine | Balmana Gelpi, Judith | Gauthier, Ludovic | Bigot, Frédéric | Goncalves, Anthony | Frenel, Jean-Sebastien | Bachelot, Thomas | Dalenc, Florence | Mailliez, Audrey | Chakiba, Camille | ... | Follana, Philippe
Journal of Clinical Oncology, volume 40, issue 16_suppl, pages TPS1116-TPS1116 (2022).
10.1200/JCO.2022.40.16_suppl.TPS1116
Cite | Source
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patien (journal article)
Berger, Frédérique | Marce, Margaux | Delaloge, Suzette | Hardy-Bessard, Anne-Claire | Bachelot, Thomas | Bièche, Ivan | Pradines, Anne | De La Motte Rouge, Thibault | Canon, Jean-Luc | André, Fabrice | ... | Bidard, François-Clement
BMJ Open, volume 12, issue 3, pages e055821- (2022).
10.1136/bmjopen-2021-055821
Cited by (28) | Cite | Source
Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer (journal article)
Migeotte, A. | Dufour, V. | van Maanen, A. | Berliere, M. | Canon, J. L. | Taylor, D. | Duhoux, F. P.
BMC Cancer, volume 21, issue 1 (2021).
10.1186/s12885-021-08950-x
Cited by (3) | Cite | Source
148P Phase III study of everolimus or placebo in addition to adjuvant hormone therapy for high risk early breast cancer: Subgroup analysis of the UCBG UNIRAD trial (journal article)
Cottu, P.H. | Dalenc, F. | Chabaud, S. | Allouache, D. | Cameron, D. | Jacquin, J-P. | Grenier, J. | Barthelemy, P. | Brunt, M. | Kaluzinski, L. | ... | Bachelot, T.
Annals of Oncology, volume 32 (2021).
10.1016/j.annonc.2021.08.429
Cite | Source
88P Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision phase II basket study (journal article)
Joris, S. | Denys, H. | Martin, M. | t'Kint de Roodenbeke, D. | Duhoux, F. | Berchem, G. | Punie, K. | Bols, A. | Mebis, J. | Canon, J-L. | ... | De Grève, J.
Annals of Oncology, volume 32 (2021).
10.1016/j.annonc.2021.08.368
Cited by (1) | Cite | Source
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer (journal article)
Lim, Bora | Potter, David A. | Salkeni, Mohamad A. | Silverman, Paula | Haddad, Tufia C. | Forget, Frederic | Awada, Ahmad | Canon, Jean-Luc | Danso, Michael | Lortholary, Alain | ... | Diamond, Jennifer R.
Clinical Cancer Research, volume 27, issue 12, pages 3329-3338 (2021).
10.1158/1078-0432.CCR-20-4131
Cited by (10) | Cite | Source
BrainStorm: A brain metastases research platform to tackle the challenge of central nervous system (CNS) metastases in solid tumors (Oncodistinct 006). (journal article)
Kotecki, Nuria | Franzoi, Maria Alice B | Paesmans, Marianne | Clatot, Florian | Borcoman, Edith | Goncalves, Anthony | Barthelemy, Philippe | Cheymol, Claire | Delord, Jean-Pierre | Gombos, Andrea | ... | Awada, Ahmad
Journal of Clinical Oncology, volume 39, issue 15_suppl, pages TPS2066-TPS2066 (2021).
10.1200/JCO.2021.39.15_suppl.TPS2066
Cite | Source
72TiP ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast (journal article)
Agostinetto, E. | Paesmans, M. | Ameye, L. | Veys, I. | Buisseret, L. | Neven, P. | Taylor, D. | Fontaine, C. | Duhoux, F.P. | Canon, J-L. | ... | Aftimos, P.G.
Annals of Oncology, volume 32 (2021).
10.1016/j.annonc.2021.03.086
Cite | Source
Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer (journal article)
Bachelot, T. | Dalenc, F. | Chabaud, S. | Cottu, P. | Allouache, D. | Brain, E. | Jacquin, J-P. | Grenier, J. | Bouvet, L. Venat | Brunt, M. | ... | André, F.
Annals of Oncology, volume 32, issue 4, pages 574-575 (2021).
10.1016/j.annonc.2021.02.003
Cited by (9) | Cite | Source
P15.01 AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer (journal article)
Cooke, K. | Estrada, J. | Zhan, J. | Werner, J. | Bailis, J. | Hughes, P. | Shetty, A. | Canon, J. | Smit, M.
Journal of Thoracic Oncology, volume 16, issue 3, pages S343-S344 (2021).
10.1016/j.jtho.2021.01.538
Cited by (1) | Cite | Source